ResMed (ASX:RMD) is a health technology company focused on developing, manufacturing, and marketing medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders, particularly sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases. It is listed solely on the New York Stock Exchange under the symbol (NYSE:RMD). The company's projects aim to improve patients' quality of life, reduce the impact of chronic disease, and save healthcare costs globally. ResMed is dedicated to innovation and is continuously working on expanding its product line and improving its offerings through research and development. Its objectives include enhancing patient outcomes, expanding its global footprint, and leveraging technology to make healthcare more accessible and efficient.